MAP2

Across TCGA pan-cancer cohorts, MAP2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of MAP2’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where MAP2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types MAP2 is over-expressed in tumor, although a few such as PDAC and LUAD show the opposite, repressed pattern.

PDAC, CCRCC, and LUAD are the cancer types where MAP2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MAP2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	All	III,IV	−0.878	<.001	9	view →
CCRCC	Male	All	+0.483	<.001	9	view →
LUAD	Male	All	−0.688	<.001	8	view →
LSCC	Male	III,IV	−0.971	<.001	7	view →
HNSC	Male	II,III,IV	−0.289	.014	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

MAP2–PDAC

Open the PDAC breakdown →